New Zealand markets closed

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4500+0.1000 (+7.41%)
At close: 04:00PM EDT
1.4800 +0.03 (+2.07%)
After hours: 07:59PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
Total revenue
17,667
18,256
258
4,742
Operating expenses
Research development
49,729
64,526
67,003
65,775
Selling general and administrative
43,009
41,701
21,440
15,588
Total operating expenses
101,593
106,227
79,371
67,958
Operating income or loss
-83,926
-87,971
-79,113
-63,216
Interest expense
4,545
1,940
-
-
Total other income/expenses net
-14,422
-191
432
963
Income before tax
-102,426
-89,756
-78,280
-60,925
Income from continuing operations
-102,426
-89,756
-78,280
-60,925
Net income
-102,426
-89,756
-78,280
-60,925
Net income available to common shareholders
-102,426
-89,756
-78,829
-60,925
Basic EPS
-
-2.91
-3.52
-3.35
Diluted EPS
-
-2.91
-3.52
-3.35
Basic average shares
-
30,896
22,386
18,161
Diluted average shares
-
30,896
22,386
18,161
EBITDA
-
-87,170
-78,352
-62,466